Home | FCA & regulatory news | British English edition
Trade Hub UK

Independent coverage of UK markets, FCA policy and institutional trading
AD Bank of England Statistics AD Investing.com Markets AD LSEG Data AD CME Group Education
Venues & MTFs

Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?

By Nasdaq Market Structure

Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?

Key PointsIt's a cancer medication with immense potential.

Read at source

Read also
  1. Tesla Stock Sits Nearly 30% Below Its High and Still Trades at 330 Times Earnings
  2. 2 Premier Artificial Intelligence (AI) Stocks That Can Plunge Up to 63%, According to Select Wall Street Analysts
  3. Gilead's Bixlenvo Gets FDA Approval For Virologically Suppressed Adults With HIV
  4. FDA Approves Eli Lilly's Mounjaro To Reduce Cardiovascular Risk In Type 2 Diabetes
  5. Cocoa Prices Surge on West African Cocoa Quality Concerns

Source: Nasdaq Market Structure